Table 1.
Expression of IFNγ-target proteins at baseline and post-stimulation with IFNγ in 39 melanoma cell lines.
| Cell line | Driver mutation | HLA-ABC |
HLA-DR |
NGFR |
PD-L1 |
PD-L2 |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| − | + | − | + | − | + | − | + | − | + | ||
| A2058 | BRAFV600E | 32.9 | 139.1 | 2.5 | 66.7 | 398.7 | 218.6 | 1.0 | 9.8 | 1.9 | 7.7 |
| SKMel28 | BRAFV600E | 74.2 | 128.3 | 11.1 | 120.8 | 44.7 | 197.3 | 1.3 | 2.9 | 2.6 | 10.0 |
| C060M1 | BRAFV600E | 34.9 | 88.7 | 29.5 | 75.7 | 10.4 | 16.3 | 1.0 | 5.5 | 4.3 | 6.7 |
| SCC14-0257 | BRAFV600K | 15.8 | 64.8 | 12.8 | 102.2 | 347.3 | 722.7 | 0.9 | 2.5 | 1.4 | 5.9 |
| MM418 | BRAFV600E | 38.2 | 81.8 | 1.2 | 7.7 | 16.0 | 19.0 | 1.1 | 4.0 | 1.1 | 1.5 |
| NM16 | BRAFV600E | 21.7 | 62.5 | 7.0 | 76.5 | 1,808.8 | 2,833.0 | 0.8 | 3.4 | 7.8 | 17.1 |
| NM182 | BRAFV600E | 18.9 | 143.6 | 1.3 | 31.8 | 10.1 | 14.0 | 1.0 | 4.5 | 1.0 | 1.6 |
| MM200 | BRAFV600E | 35.1 | 202.0 | 7.2 | 141.0 | 450.7 | 1,505.6 | 1.0 | 4.0 | 1.2 | 3.4 |
| NM39 | BRAFV600E | 43.6 | 122.2 | 27.6 | 123.3 | 90.7 | 46.7 | 1.1 | 3.9 | 4.3 | 17.9 |
| HT144 | BRAFV600E | 23.4 | 43.4 | 71.4 | 100.3 | 353.1 | 292.9 | 1.1 | 3.2 | 4.9 | 12.0 |
| C016M | BRAFV600E | 20.9 | 70.3 | 42.7 | 95.9 | 469.6 | 630.2 | 0.9 | 1.3 | 2.2 | 5.5 |
| MelRm | NRASQ61R | 36.9 | 98.7 | 102.8 | 252.5 | 18.4 | 75.2 | 0.9 | 2.3 | 1.6 | 3.4 |
| NM47 | NRASQ61R | 42.1 | 109.0 | 157.9 | 249.0 | 213.6 | 1,034.1 | 1.0 | 2.5 | 1.8 | 2.9 |
| NM177 | NRASQ61R | 56.5 | 99.7 | 76.6 | 92.9 | 3,674.9 | 3,663.2 | 1.0 | 1.9 | 2.0 | 3.4 |
| NM179 | NRASQ61K | 12.7 | 31.1 | 2.4 | 59.6 | 44.2 | 85.4 | 1.0 | 3.3 | 1.7 | 6.6 |
| ME4405 | NRASQ61R | 60.5 | 118.2 | 0.9 | 0.9 | 24.0 | 47.3 | 1.0 | 2.1 | 3.5 | 14.2 |
| MelAT | NRASQ61R | 31.9 | 121.3 | 0.9 | 1.0 | 11.8 | 27.4 | 1.2 | 2.0 | 2.0 | 10.3 |
| D11M2 | NRASQ61L | 11.3 | 18.4 | 16.4 | 33.7 | 29.2 | 32.1 | 1.1 | 2.4 | 3.3 | 9.2 |
| C002M | NRASQ61K | 7.2 | 31.4 | 1.0 | 27.0 | 13.7 | 15.6 | 1.2 | 2.3 | 1.4 | 1.5 |
| C013M | NRASQ61L | 24.7 | 81.1 | 1.0 | 42.7 | 47.8 | 199.3 | 1.0 | 2.3 | 2.2 | 6.5 |
| D38M2 | NRASQ61R | 28.6 | 86.2 | 4.5 | 56.5 | 509.6 | 480.4 | 1.1 | 2.4 | 2.9 | 12.2 |
| D22M1 | BRAF/NRASWT | 28.0 | 25.7 | 1.9 | 1.9 | 5.8 | 5.3 | 1.3 | 1.1 | 1.3 | 1.2 |
| MeWo | BRAF/NRASWT | 28.9 | 107.6 | 1.4 | 19.1 | 268.9 | 176.2 | 0.9 | 2.2 | 1.3 | 4.2 |
| D24M | BRAF/NRASWT | 32.6 | 37.2 | 13.8 | 43.3 | 30.7 | 28.3 | 1.2 | 3.3 | 7.3 | 31.0 |
| C022M1 | BRAF/NRASWT | 10.7 | 41.7 | 2.3 | 21.5 | 148.3 | 341.0 | 1.9 | 1.6 | 1.1 | 1.8 |
| C084M | BRAF/NRASWT | 83.6 | 119.0 | 19.5 | 130.4 | 552.5 | 631.5 | 0.9 | 4.6 | 3.2 | 15.7 |
| C086M | BRAF/NRASWT | 20.1 | 52.4 | 22.7 | 90.3 | 1.3 | 2.9 | 1.1 | 3.0 | 3.7 | 9.9 |
| D35 | BRAF/NRASWT | 167.9 | 460.2 | 3.8 | 129.6 | 21.9 | 36.9 | 0.9 | 2.9 | 0.9 | 2.7 |
| C025M1 | BRAF/NRASWT | 73.2 | 134.1 | 2.1 | 18.5 | 1.7 | 2.7 | 1.1 | 2.7 | 1.1 | 1.2 |
| SMU15-0217 | BRAF/NRASWT | 1.5 | 2.1 | 12.8 | 91.4 | 11.0 | 26.0 | 1.2 | 3.4 | 4.4 | 22.3 |
| A04-GEH | BRAF/NRASWT | 23.9 | 96.6 | 1.5 | 63.3 | 13.8 | 45.9 | 1.0 | 2.9 | 1.2 | 8.2 |
| 92.1 | GNAQQ209L | 11.5 | 87.2 | 0.5 | 0.5 | 14.0 | 38.8 | 1.1 | 1.7 | 1.2 | 1.0 |
| MEL202 | GNAQQ209L, R210K | 38.2 | 346.3 | 1.1 | 15.9 | 10.6 | 15.0 | 1.0 | 5.6 | 1.0 | 2.7 |
| MEL270 | GNAQQ209P | 52.5 | 115.6 | 1.1 | 1.8 | 3.6 | 4.1 | 1.1 | 1.6 | 1.2 | 1.3 |
| MP38 | GNAQQ209P | 73.5 | 329.7 | 1.6 | 10.6 | 10.6 | 15.8 | 1.1 | 2.4 | 2.9 | 25.3 |
| OMM1 | GNA11Q209L | 31.2 | 108.0 | 1.1 | 19.0 | 2.0 | 3.6 | 1.1 | 1.5 | 1.0 | 3.7 |
| MP41 | GNA11Q209L | 26.3 | 44.2 | 0.9 | 3.7 | 2.6 | 3.6 | 0.9 | 1.3 | 1.1 | 2.0 |
| MP46 | GNAQQ209L | 2.3 | 38.6 | 1.0 | 1.0 | 5.2 | 10.6 | 1.1 | 1.5 | 1.0 | 1.6 |
| MM28 | GNA11Q209L | 9.4 | 50.8 | 1.1 | 13.1 | 1.3 | 1.7 | 1.0 | 2.1 | 1.0 | 2.1 |
Relative marker expression levels were calculated by dividing the geometric mean fluorescence intensity (MFI) of the antibody-stained sample by the FMO control MFI.
−, no IFNγ treatment; +, treated for 72 h with 1,000 U/ml IFNγ; IFNγ, interferon-γ; NGFR, nerve growth factor receptor; FMO, fluorescence minus one.